Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Neos Therapeutics Inc's Business Segments
Neos Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 13
Regions Reported
-
Neos Therapeutics Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Adzenys Product49.3%
- Cotempla Xr Odt44.6%
- Generic Tussionex Product5.3%
- Adzenys Er0.8%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Adzenys Product | $ 6 | 49.3% |
| Cotempla Xr Odt | $ 6 | 44.6% |
| Generic Tussionex Product | $ 1 | 5.3% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
1 more categories available
Sign in to unlock the full Neos Therapeutics Inc dataset.
Description of Neos Therapeutics Inc
Neos Therapeutics Inc is a biopharmaceutical company that specializes in the development and commercialization of innovative extended-release (XR) products for the treatment of attention-deficit/hyperactivity disorder (ADHD) and other central nervous system (CNS) disorders. The company was founded in 1989 and is headquartered in Grand Prairie, Texas.
Neos Therapeutics focuses on developing XR formulations of existing medications to provide patients with better treatment options that require less frequent dosing. They aim to improve patient compliance and convenience while maximizing therapeutic efficacy. The company's unique technology platform, known as XR-ODT (extended-release orally disintegrating tablet), allows for immediate and controlled drug release over an extended period.
ADHD is a disorder that affects both children and adults and is characterized by symptoms such as impulsivity, hyperactivity, and inattention. Neos Therapeutics' flagship product is Adzenys XR-ODT, an extended-release amphetamine product approved by the U.S. Food and Drug Administration (FDA) for the treatment of ADHD. Adzenys XR-ODT provides patients with a once-daily dosing option and is the first and only extended-release ADHD medication available in an orally disintegrating tablet format.
In addition to Adzenys XR-ODT, Neos Therapeutics also developed Cotempla XR-ODT, another extended-release amphetamine product for the treatment of ADHD. Cotempla XR-ODT offers a flexible dosing option, allowing physicians to individualize treatment for each patient's needs.
Neos Therapeutics has a strong commitment to improving patient outcomes by providing innovative treatment options. The company conducts extensive research and development activities to expand its product pipeline and address unmet medical needs in the field of CNS disorders. They collaborate with key opinion leaders, physicians, and patients to gain insights and develop products that deliver significant benefits to patients.
Apart from its focus on product development, Neos Therapeutics also prioritizes ensuring affordability and access to its medications for patients. They have a patient assistance program called Neos RxConnect that helps eligible patients access their prescribed medications at affordable or no cost.
In conclusion, Neos Therapeutics Inc is a biopharmaceutical company dedicated to developing and commercializing extended-release products for the treatment of ADHD and other CNS disorders. They leverage their XR-ODT technology platform to provide innovative treatment options that enhance patient compliance and convenience. With their flagship products, Adzenys XR-ODT and Cotempla XR-ODT, Neos Therapeutics aims to improve patient outcomes and address unmet medical needs in the field of ADHD.
Neos Therapeutics focuses on developing XR formulations of existing medications to provide patients with better treatment options that require less frequent dosing. They aim to improve patient compliance and convenience while maximizing therapeutic efficacy. The company's unique technology platform, known as XR-ODT (extended-release orally disintegrating tablet), allows for immediate and controlled drug release over an extended period.
ADHD is a disorder that affects both children and adults and is characterized by symptoms such as impulsivity, hyperactivity, and inattention. Neos Therapeutics' flagship product is Adzenys XR-ODT, an extended-release amphetamine product approved by the U.S. Food and Drug Administration (FDA) for the treatment of ADHD. Adzenys XR-ODT provides patients with a once-daily dosing option and is the first and only extended-release ADHD medication available in an orally disintegrating tablet format.
In addition to Adzenys XR-ODT, Neos Therapeutics also developed Cotempla XR-ODT, another extended-release amphetamine product for the treatment of ADHD. Cotempla XR-ODT offers a flexible dosing option, allowing physicians to individualize treatment for each patient's needs.
Neos Therapeutics has a strong commitment to improving patient outcomes by providing innovative treatment options. The company conducts extensive research and development activities to expand its product pipeline and address unmet medical needs in the field of CNS disorders. They collaborate with key opinion leaders, physicians, and patients to gain insights and develop products that deliver significant benefits to patients.
Apart from its focus on product development, Neos Therapeutics also prioritizes ensuring affordability and access to its medications for patients. They have a patient assistance program called Neos RxConnect that helps eligible patients access their prescribed medications at affordable or no cost.
In conclusion, Neos Therapeutics Inc is a biopharmaceutical company dedicated to developing and commercializing extended-release products for the treatment of ADHD and other CNS disorders. They leverage their XR-ODT technology platform to provide innovative treatment options that enhance patient compliance and convenience. With their flagship products, Adzenys XR-ODT and Cotempla XR-ODT, Neos Therapeutics aims to improve patient outcomes and address unmet medical needs in the field of ADHD.
As of the last available information, Neos Therapeutics, Inc. was a pharmaceutical company focused primarily on the development and commercialization of innovative products for the treatment of attention deficit hyperactivity disorder (ADHD) and other central nervous system (CNS) disorders. Below is an extensive overview of the segments, products, and services that Neos Therapeutics offered:
Segments
1. Pharmaceutical Development:
- Neos Therapeutics is heavily invested in developing pharmaceutical formulations specifically tailored for the treatment of ADHD and other CNS-related disorders. This segment includes the research and development (R&D) of novel drug formulations that improve patient compliance and provide optimized delivery mechanisms.
2. Commercialization:
- The company engages in the commercialization of its developed products, focusing on marketing strategies and partnerships to enhance the accessibility of its medications. This segment encompasses direct sales efforts, collaborations with healthcare providers, and outreach programs to patients and caregivers.
3. Research Collaborations:
- Neos collaborates with various research institutions and universities to advance its R&D initiatives. These partnerships are aimed at innovating new therapeutic approaches for ADHD and related disorders, expanding the companys pipeline of potential products.
Products
Neos Therapeutics has concentrated on pharmaceutical products primarily in the ADHD space. Key products include:
1. Adzenys XR-ODT (Amphetamine):
- A once-daily orally disintegrating tablet for the treatment of ADHD in patients aged six years and older. This product is designed to dissolve on the tongue without the need for water, making it more convenient for patients, particularly children and adolescents.
- The formulation allows for a gradual release of the active ingredient, providing extended therapeutic effects throughout the day.
2. Adzenys ER (Amphetamine):
- An extended-release oral capsule that provides an alternative for ADHD treatment. This formulation offers a different dosage form and release mechanism compared to Adzenys XR-ODT, catering to varying patient preferences and adherence needs.
3. Cotempla XR-ODT (Methylphenidate):
- Another orally disintegrating tablet option available for the treatment of ADHD. Cotempla XR-ODT is specifically indicated for patients aged six years and older and utilizes a similar dosage form to Adzenys XR-ODT, offering flexibility in treatment options.
Services
Neos Therapeutics also provides a range of services designed to support patients, caregivers, and healthcare providers:
1. Patient Support Programs:
- Neos offers patient support programs aimed at enhancing medication adherence and providing education about ADHD and its management. These programs may include access to resources such as educational materials, counseling, and support groups.
2. Healthcare Provider Education:
- The company engages in educational outreach to healthcare professionals, focusing on the clinical benefits of its medications, emerging treatment paradigms for ADHD, and best practices in patient management.
3. Reimbursement Support:
- Neos assists patients and healthcare providers with navigating insurance reimbursement processes to ensure accessibility to its medications. This may involve providing information on prior authorizations, co-pay assistance programs, and other financial supports.
Summary
In summary, Neos Therapeutics, Inc. is focused on developing innovative therapies for ADHD through its comprehensive product portfolio, which includes unique formulations that cater to diverse patient needs. The company also emphasizes extensive support for patients and healthcare providers through educational initiatives, patient programs, and reimbursement support, all designed to improve treatment outcomes in ADHD management. This approach reflects Neoss commitment to addressing the challenges faced by those living with ADHD and its importance in promoting better health and quality of life for patients.
Segments
1. Pharmaceutical Development:
- Neos Therapeutics is heavily invested in developing pharmaceutical formulations specifically tailored for the treatment of ADHD and other CNS-related disorders. This segment includes the research and development (R&D) of novel drug formulations that improve patient compliance and provide optimized delivery mechanisms.
2. Commercialization:
- The company engages in the commercialization of its developed products, focusing on marketing strategies and partnerships to enhance the accessibility of its medications. This segment encompasses direct sales efforts, collaborations with healthcare providers, and outreach programs to patients and caregivers.
3. Research Collaborations:
- Neos collaborates with various research institutions and universities to advance its R&D initiatives. These partnerships are aimed at innovating new therapeutic approaches for ADHD and related disorders, expanding the companys pipeline of potential products.
Products
Neos Therapeutics has concentrated on pharmaceutical products primarily in the ADHD space. Key products include:
1. Adzenys XR-ODT (Amphetamine):
- A once-daily orally disintegrating tablet for the treatment of ADHD in patients aged six years and older. This product is designed to dissolve on the tongue without the need for water, making it more convenient for patients, particularly children and adolescents.
- The formulation allows for a gradual release of the active ingredient, providing extended therapeutic effects throughout the day.
2. Adzenys ER (Amphetamine):
- An extended-release oral capsule that provides an alternative for ADHD treatment. This formulation offers a different dosage form and release mechanism compared to Adzenys XR-ODT, catering to varying patient preferences and adherence needs.
3. Cotempla XR-ODT (Methylphenidate):
- Another orally disintegrating tablet option available for the treatment of ADHD. Cotempla XR-ODT is specifically indicated for patients aged six years and older and utilizes a similar dosage form to Adzenys XR-ODT, offering flexibility in treatment options.
Services
Neos Therapeutics also provides a range of services designed to support patients, caregivers, and healthcare providers:
1. Patient Support Programs:
- Neos offers patient support programs aimed at enhancing medication adherence and providing education about ADHD and its management. These programs may include access to resources such as educational materials, counseling, and support groups.
2. Healthcare Provider Education:
- The company engages in educational outreach to healthcare professionals, focusing on the clinical benefits of its medications, emerging treatment paradigms for ADHD, and best practices in patient management.
3. Reimbursement Support:
- Neos assists patients and healthcare providers with navigating insurance reimbursement processes to ensure accessibility to its medications. This may involve providing information on prior authorizations, co-pay assistance programs, and other financial supports.
Summary
In summary, Neos Therapeutics, Inc. is focused on developing innovative therapies for ADHD through its comprehensive product portfolio, which includes unique formulations that cater to diverse patient needs. The company also emphasizes extensive support for patients and healthcare providers through educational initiatives, patient programs, and reimbursement support, all designed to improve treatment outcomes in ADHD management. This approach reflects Neoss commitment to addressing the challenges faced by those living with ADHD and its importance in promoting better health and quality of life for patients.